Diglycerol monooleate

Other Names

(Z)-9-Octadecenoic acid 2,6,7-trihydroxy-4-oxaheptane-1-yl ester(Z)-9-Octadecenoic acid 2-hydroxy-3-(2,3-dihydroxypropoxy)propyl ester(Z)-9-Octadecenoic acid 3-(2,3-dihydroxypropoxy)-2-hydroxypropyl ester3-(2,3-Dihydroxypropoxy)-2-hydroxypropyl oleate9-Octadecenoic acid (Z)-, monoester with oxybis(propanediol)9-Octadecenoic acid, ester with 1,2,3-propanetriol9-Octadecenoic acid, monoester with oxybis(propanediol)DGMODiglyceryl monooleateOleic acid 2,6,7-trihydroxy-4-oxaheptan-1-yl esterOleic acid 3-(2,3-dihydroxypropoxy)-2-hydroxypropyl esterOleic acid, monoester with oxybis(propanediol)Polyglyceryl-2 oleate

Synopsis

Diglycerol Monooleate (DGMO): A Comprehensive Reference

1. Identity and Chemical Characterization

Names, Synonyms, and Identifiers

Diglycerol monooleate (commonly abbreviated DGMO) is the monoester formed by the esterification of diglycerol with oleic acid. It belongs to the broader family of polyglycerol fatty acid esters. Its systematic IUPAC names include oleic acid 3-(2,3-dihydroxypropoxy)-2-hydroxypropyl ester and (Z)-9-octadecenoic acid 2,6,7-trihydroxy-4-oxaheptane-1-yl ester. The CAS registry number is 97605-97-5, and it carries the EINECS number 3073684.

Its molecular formula is C₂₄H₄₆O₆ with a molecular weight of approximately 430.63 g/mol. A related isomeric form has also been catalogued under CAS 49553-76-6. Within the European food and cosmetic regulatory frameworks, diglycerol monooleate is classifiable under E475 (polyglycerol esters of fatty acids).

The compound is structurally distinct from the simpler glycerol monooleate (GMO, monoolein, CAS 25496-72-4). Both compounds share the same hydrophobic C18:1 (oleic acid) chain but differ in their polar headgroups: DGMO possesses a diglycerol headgroup (two glycerol units linked via an ether oxygen), conferring a larger, more hydrophilic head section than GMO. This structural difference has profound consequences for its self-assembly and phase behavior in water.

Physical and Physicochemical Properties

DGMO is a nonionic amphiphilic molecule. Commercial grades, such as the NIKKOL DGMO-90V preparation, are described as high-purity products. DGMO is a lipophilic nonionic surfactant with excellent salt and acid resistance and high safety; it is a diglycerol fatty acid ester consisting of glycerol and oleic acid derived from vegetable oil, with approximately 90% monoester content. Its hydrophilic–lipophilic balance (HLB) value is approximately 6.5, making it primarily suited for water-in-oil (W/O) emulsification.

DGMO belongs to the class of diglycerol esters of fatty acids with a C18:1 (cis-oleic acid) chain and shows a much stronger reduction in interfacial tension at low concentrations (0.01–0.1%) than corresponding monoglycerides. In water, DGMO forms lamellar phases across a temperature range from zero to 80°C — in strong contrast to the corresponding glycerol monooleate, which forms cubic and reversed hexagonal mesophases in water.

Natural Source and Relationship to Naturally Occurring Lipids

DGMO does not occur as a major distinct component in any known botanical or animal source in isolation. It is, however, a structural member of the broader family of polyglycerol fatty acid esters that arise naturally in small amounts during lipid metabolism or industrial processing of fats. The growing interest in environmentally friendly products has increased interest in biodegradable nonionic surfactant products; polyglycerol fatty acid esters have a wide field of application in many industries as additives in cosmetics, food, photography, and inks. The oleic acid component (C18:1) that forms DGMO's hydrophobic tail is an abundant naturally occurring monounsaturated fatty acid found in olive oil, sunflower oil, and numerous other vegetable and animal fats.

Oleic acid as a precursor is typically sourced from edible vegetable oils. The fatty acid chains used in the synthesis of polyglycerol fatty acid esters can be derived from various sources including soybean oil, palm oil, and other vegetable oils.

2. Synthesis and Commercial Preparation

Conventional Chemical Synthesis

Conventional production of polyglycerol esters by esterification commonly involves the use of either alkali or acid catalysts; however, these catalysts favor side-reactions including degradation of the fatty acid (oxidation and dimerization) or degradation of the polyglycerol (dehydration to acrolein and oxidation).

In one well-documented industrial preparation process, a polyglycerol composition comprising approximately 97% or greater diglycerol and 3% or less triglycerol is esterified with fatty acids comprising approximately 71% C18:1, 4% C18:2, 9% C16:1, 5% C16:0, and 11% other fatty acids, in a polyglycerol:fatty acid weight ratio of approximately 60:40, using sodium hydroxide as a catalyst at about 225°C under conditions of mechanical agitation, nitrogen sparging, and gradually increasing vacuum, with subsequent phosphoric acid neutralization, cooling to about 85°C, and settling to reduce the level of unreacted polyglycerols.

Enzymatic (Green Chemistry) Synthesis

A few decades ago, the employment of lipases as biocatalysts for esterification reactions emerged as a potential route to replace conventional chemical processes, as they are active and selective catalysts in a variety of reactions with fewer environmental problems, and in the case of immobilized lipases, they can be reused.

The lipase-catalyzed esterification of pure diglycerol (3-(2,3-dihydroxypropoxy)propane-1,2-diol) with pure oleic acid to produce pure diglycerol monooleate was optimized; six immobilized lipases were tested and the best oleic acid conversion was attained with Novozym 435 from Candida antarctica, which was selected to optimize the reaction conditions by response surface methodology (RSM). A well-fitting quadratic polynomial regression model for acid conversion was established with regard to temperature (65°C–75°C) and catalyst concentration (mass fraction of 1–5%), with catalyst concentration having the greatest effect.

Common Commercial Forms

DGMO is commercially available in several forms for pharmaceutical, food, and cosmetic applications. Notable preparations include:

NIKKOL DGMO-90V (Nikko Chemicals, Japan): a diglycerol fatty acid ester consisting of glycerol and oleic acid derived from vegetable oil, presented as a lipophilic nonionic surfactant with approximately 90% monoester content.
Research-grade DGMO (e.g., from NOF Corporation): Commercial glycerol monooleate preparations from NOF Co. may contain a mixture of glycerol monooleate as the main component plus oleic acid and DGMO in small amounts.
DGMO in combination with glycerol monooleate-rich mixtures (such as Capmul GMO-50), used as a component system for nanoparticle formulation, as documented in multiple peer-reviewed studies.

3. Traditional and Historical Use

Diglycerol monooleate as an isolated, characterized compound does not appear in documented pre-modern or traditional pharmacopeial or botanical literature, as it is a chemically defined polyglycerol ester rather than a plant extract or traditionally recognized natural product. Polyglycerol esters as a class are products of 20th-century food and chemical technology.

Polyglycerol esters are a class of food emulsifiers used extensively within the food industry because of their amphiphilic nature in various types of food; they are produced from polyglycerol and fatty acids in a direct esterification of triglycerides and polyglycerol. They are nonionic emulsifiers exhibiting a broad range of polarity or hydrophilic-lipophilic balance (HLB) values, ranging from 6 to 11, and their broad range of HLB values makes them a versatile emulsifier for food applications.

The broader use of glycerides as food ingredients, including monoglycerides and diglycerides, has a longer established food safety history. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) concluded in 1973 that there is no risk to human health from exposure to mono- and diglycerides, stating that "mono- and di-glycerides differed little from food so that their use need not to be limited," and JECFA set a "not limited" acceptable daily intake (ADI).

There is no peer-reviewed ethnobotanical or traditional medicine documentation for DGMO specifically. The constituent components — diglycerol (a condensation product of glycerol) and oleic acid — are both common in nature and diet, but their specific esterification product DGMO is a defined industrial/scientific entity emerging from late 20th-century food science and colloid chemistry research.

4. Key Constituents and Chemical Composition

DGMO is itself the active chemical entity. Its structure integrates:

Diglycerol headgroup: Two glycerol units joined by an ether linkage (3-(2,3-dihydroxypropoxy)propane-1,2-diol), providing three free hydroxyl groups and high hydrophilicity.
Oleic acid tail: A C18:1 (cis, Δ9) monounsaturated fatty acid chain, providing the lipophilic domain and the characteristic amphiphilic architecture.

The amphiphilic properties of polyglycerol esters in water exhibit mesomorphic activity, forming liquid crystalline structures. The precise ratio of mono- versus di-ester content in commercial preparations varies by manufacturer and synthesis method; high-purity commercial grades target approximately 90% monoester content as noted for the NIKKOL DGMO-90V preparation.

It is informative to compare diglycerol esters with monoglycerides, which are the most widely used food emulsifiers and are closely related in molecular structure to diglycerol esters. The extra glycerol unit in the headgroup of DGMO, compared to glycerol monooleate, results in distinctly different mesophase behavior and a greater degree of surface activity at low concentrations.

5. Mechanisms of Action

Interfacial and Emulsification Activity

The surface activity of DGMO has been investigated systematically; diglycerol esters show a much stronger reduction in the interfacial tension at low concentrations (0.01–0.1%) than corresponding monoglycerides. This strong surface-active character is attributed to the multiple hydroxyl groups in the diglycerol headgroup, which allow extensive hydrogen bonding with water while the oleic acid chain anchors into the hydrophobic phase.

Diglycerol esters form lamellar mesophases above their Krafft point; the lamellar phases show a limited swelling capacity, corresponding to a water layer thickness of approximately 24 Å when the ratio of diglycerol ester to water is 60:40 or lower. At high water concentrations (>90%), multi-lamellar liposomes are formed.

Lyotropic Liquid Crystalline Phase Formation

A defining mechanistic feature of DGMO is its ability to self-assemble into a rich variety of liquid crystalline structures in aqueous media, depending on composition, temperature, and the presence of co-lipids. Studies of the aqueous phase behavior of DGMO/glycerol dioleate (GDO) mixtures, examined by X-ray diffraction, show a ternary phase diagram displaying a multitude of liquid crystalline phases (polymorphism). With increasing GDO content, the following phase sequence was observed: lamellar (Lα); two reversed bicontinuous cubic phases (Q₂³⁰ and Q₂²⁴); reversed hexagonal (H₂); and the reversed micellar (L₂) phase.

The three-component lipid system composed of DGMO, glycerol dioleate (GDO), and polysorbate 80 (P80) exhibits several advantageous features relating to drug delivery applications including spontaneous dispersion formation with a narrow size distribution and tunable particle phase-structure. The obtained phase diagram shows the presence of lamellar (Lα), hexagonal (H₂), and reverse bicontinuous cubic (V₂) liquid crystalline phases and an inverse micellar (L₂) solution.

The sponge phase features a network of aqueous cavities separated by curved lipid bilayers, but with a more flexible structure and larger water cavities compared to the inverse bicontinuous cubic phase. This distinct capacity to form an L3 sponge phase — rather than the cubic phases typically generated by pure glycerol monooleate — is a critical mechanistic distinction. The lipid liquid crystalline sponge phase (L3) is a nanoscopically bicontinuous bilayer network able to accommodate large amounts of water and is easy to manipulate due to its fluidity; L3 phases can produce water channels large enough to encapsulate bioactive macromolecules such as proteins.

Absorption Enhancement

For the parent compound glycerol monooleate, and by structural analogy for DGMO-based formulations, glycerol monooleate has been used as an absorption enhancer in combination with bile salts; it probably acts by causing a temporary and reversible disruption of the lamellar structure of the lipid bilayer in the stratum corneum, thereby increasing intercellular lipid fluidity. Whether DGMO itself exerts a comparable direct absorption-enhancing effect on biological membranes has not been established independently in peer-reviewed clinical studies; its principal mechanistic utility lies in forming structured lipid nanocarriers.

Metabolic Fate

As an ester of a fatty acid (oleic acid) and diglycerol, DGMO is expected to be cleaved by tissue esterases following the general metabolic fate of glyceride esters. Glycerol monooleate (GMO) and related glycerides are classified as GRAS due to their biodegradability, biocompatibility, and minimal toxicity; biodegradability is attributed to the lipolysis of GMOs in different tissues via esterase activity. While this specific mechanism is established for GMO, DGMO shares the same ester linkage and oleic acid moiety, and the diglycerol backbone is itself a metabolite of glycerol. There are no published pharmacokinetic or metabolic studies specifically quantifying DGMO's degradation products or their kinetics in humans.

6. Scientific Evidence by Area of Use

6.1 Drug Delivery — Lipid Liquid Crystalline Nanoparticles

The most extensively documented scientific application of DGMO is as a structural component of lipid nanoparticle drug delivery systems, specifically sponge-phase nanoparticles (spongosomes), hexosomes, and related non-lamellar liquid crystalline nanoparticles (LCNPs). This is primarily a pharmaceutical materials science application rather than a direct dietary supplement use.

Lipid nanoparticles of nonlamellar lyotropic phases have a wide solubilizing and encapsulating spectrum for a range of substances, thanks to their nanostructured interior featuring both lipophilic and hydrophilic domains; as a consequence, these systems have emerged as promising drug delivery systems in various pharmaceutical and diagnostic applications.

A landmark 2006 study published in Langmuir characterized the sponge nanoparticle dispersions formed from DGMO, glycerol dioleate, and polysorbate 80. The three-component lipid system composed of DGMO, GDO, and P80 was shown to have several advantageous features relating to drug delivery applications, including spontaneous dispersion formation with a narrow size distribution and tunable particle phase-structure, with a phase diagram showing lamellar, hexagonal, and reverse bicontinuous cubic phases as well as an inverse micellar solution.

A 2016 study published in Langmuir by Valldeperas et al. characterized the L3 phase behavior of DGMO/GMO-50 systems in detail. The aqueous phase behavior of a lipid mixture system consisting of DGMO and a mixture of mono-, di-, and triglycerides (Capmul GMO-50) was studied, and sponge-like nanoparticles (NPs) were also characterized. The lipid liquid crystalline sponge phase (L3) has the advantage of being a nanoscopically bicontinuous bilayer network able to accommodate large amounts of water and being easy to manipulate due to its fluidity; L3 phases with water channels large enough to encapsulate bioactive macromolecules such as proteins were characterized in detail.

It has been previously observed that mixtures of glycerides enriched in glycerol monooleate (Capmul GMO-50) and diglycerol monooleate (DGMO) can form sponge phases (L3) in mixtures with water. More recent work (2025, Frontiers in Soft Matter) extended this finding by examining the effect of adding the phospholipid DOPC on the sponge phase properties of GMO-50/DGMO/P80/water systems. The study was based on food-grade lipid mixtures of GMO-50, DGMO, polysorbate 80, and water, which are known to form sponge phases; non-lamellar LLC nano-systems are being exploited as delivery systems for therapeutic proteins, peptides, or nucleic acids, given their ability to host a wide variety of hydrophilic, hydrophobic, and amphiphilic small molecules as well as biomacromolecules.

Evidence strength: All current evidence for DGMO-based drug delivery is preclinical (physicochemical characterization, in vitro encapsulation, and cell-line studies). No published human clinical trials have used DGMO-based nanoparticles as the primary delivery vehicle for a therapeutic agent. The evidence base is robust at the materials science level but preliminary with respect to clinical efficacy and safety in humans.

6.2 Food Technology — Emulsification, Foaming, and Texture Modification

DGMO has been studied as a food-grade emulsifier, particularly in the context of protein-stabilized emulsions and foams. Many food emulsions are stabilized by proteins or mixed emulsifier–protein interfacial films, and only few food-grade emulsifiers are able to stabilize protein-free emulsions; accordingly, the effect of diglycerol monooleate in O/W emulsions with and without milk proteins has been a subject of investigation.

E471 (the broader class of mono- and di-glycerides to which related glycerides belong) is widely used for purposes such as emulsifier, starch complexing agent, and aerating agent. Diglycerol esters of fatty acids, including DGMO, fall under the broader E475 (polyglycerol esters) regulatory category in Europe when synthesized with diglycerol, or may be part of E471 formulations. An important application of polyglycerol esters is in cake batters with little or no content of fat and oil.

Evidence strength: Use of DGMO as a food emulsifier is supported by physicochemical and food science studies and regulatory assessments. There are no clinical intervention trials measuring health outcomes from consumption of DGMO specifically as a dietary supplement.

6.3 Cosmetics and Topical Applications

DGMO and related diglycerol esters are used as emulsifiers and skin-conditioning agents in cosmetic formulations. As a lipophilic nonionic surfactant, DGMO has excellent salt and acid resistance and high safety. The parent compounds glycerol monooleate and oleic acid have well-characterized dermatological profiles. Glycerol monooleate has been used in the pharmaceutical area as an emulsifier and absorption enhancer in combination with bile salts; as an absorption enhancer it probably acts by causing a temporary and reversible disruption of the lamellar structure of the lipid bilayer in the stratum corneum, increasing intercellular lipid fluidity.

Glyceryl oleate (the glyceryl 1-monoester of oleic acid) is used in cosmetic products as an emulsifier at concentrations up to 5%; oral administration of a single 13 ml/kg dose of a sunscreen formulation containing 5% glyceryl oleate to rats produced no signs of toxicity and no lethality; a single exposure of undiluted glyceryl oleate in animal dermal irritation studies produced only minimal irritation.

Evidence strength: Safety data for topical DGMO specifically are limited; most existing toxicological profiles in the literature relate to the parent monoglyceride glyceryl oleate, not to the diglycerol ester specifically. No human dermatology clinical trials specifically testing DGMO as an active ingredient are documented in the peer-reviewed literature.

6.4 Protein Encapsulation and Biopharmaceutical Applications

A particularly investigated application of DGMO-containing formulations is the encapsulation of macromolecular drugs, including proteins and enzymes, within the large aqueous channels of the L3 sponge phase. The lipid liquid crystalline sponge phase (L3) has the advantages of being a nanoscopically bicontinuous bilayer network able to accommodate large amounts of water and being easy to manipulate due to its fluidity; L3 phases have been characterized with water channels large enough to encapsulate bioactive macromolecules such as proteins.

Previous studies have demonstrated the effective entrapment of enzymes within lipid sponge nanoparticles, highlighting their potential as versatile delivery vehicles. Characterization in these studies relied on methods including dynamic light scattering (DLS), cryo-transmission electron microscopy (Cryo-TEM), and small-angle X-ray scattering (SAXS). Evidence remains at the preclinical, in vitro level; no clinical trials in humans encapsulating proteins via DGMO-based sponge particles have been published.

6.5 Oral Drug Bioavailability Enhancement (Related Lipid Systems)

Although this work focuses on glycerol monooleate rather than DGMO per se, it establishes the pharmacological context for DGMO-containing lipid systems. Lipid-based liquid crystals formed from phytantriol (PHY) and glyceryl monooleate (GMO) retain their cubic-phase structure upon dilution in physiologically relevant simulated gastrointestinal media, suggesting potential application as sustained-release drug-delivery systems for poorly water-soluble drugs; the potential of PHY and GMO to serve as sustained-release lipid vehicles for the poorly water-soluble drug cinnarizine was assessed and compared to an aqueous suspension. The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension; the PHY formulation provided a T(max) for cinnarizine of 33 h, with absorption apparent up to 55 h after administration, while the T(max) for the GMO formulation was only 5 h. This animal (rat) study illustrates the general principle that monoolein-based lipid systems can meaningfully alter drug bioavailability, but DGMO specifically has not been the subject of published in vivo bioavailability studies.

7. Body Systems and Health Areas

Based on the available scientific literature, DGMO is associated with the following body systems and application areas, though it must be emphasized that evidence in humans is largely absent:

Gastrointestinal system (drug delivery): DGMO-based lipid nanoparticles are being investigated as oral drug delivery matrices. Non-lamellar LLC nano-systems are being exploited as delivery systems for therapeutic proteins, peptides, or nucleic acids, given their ability to host a wide variety of hydrophilic, hydrophobic, and amphiphilic small molecules as well as biomacromolecules.
Skin and integumentary system (topical delivery): DGMO's amphiphilic properties and its structural kinship to glycerol monooleate mean it is used in cosmetic emulsions and has been proposed for topical drug delivery formulations, exploiting its emulsifying and barrier-modifying properties.
Parenteral and systemic delivery (preclinical): Functional drug delivery and gene transfection systems require formulations that have low cytotoxicity and good ability to be tailored for targeted delivery and controlled release. DGMO-based sponge nanoparticles have been characterized in this context in preclinical settings.
Digestive/metabolic: As a lipid ester, DGMO is metabolized via esterase-dependent lipolysis, yielding diglycerol and oleic acid — metabolites that enter normal lipid metabolic pathways. No specific metabolic health claims for DGMO are supported by clinical evidence.

8. Dosage Forms and Reported Use Levels

DGMO is not currently an established dietary supplement ingredient with defined clinical doses. Reported use levels are exclusively from food technology, pharmaceutical formulation research, and cosmetic applications:

Pharmaceutical nanoparticle formulations: A novel lipid mixture system consisting of DGMO and Capmul GMO-50 was studied for sponge nanoparticle formulation; sponge-like nanoparticles stabilized by Polysorbate 80 were prepared based on the DGMO/GMO-50 system. Specific ratios studied in publications (by Valldeperas et al., 2016, Langmuir) involve varying DGMO/GMO-50 weight ratios to map the sponge phase region, but no clinical dose has been established.
Cosmetic formulations: DGMO is presented in cosmetic-grade preparations with approximately 90% monoester content. No specific concentration ranges for DGMO in cosmetic products are provided in the available peer-reviewed literature.
Industrial synthesis: Optimization studies for enzymatic synthesis of DGMO used temperatures of 65°C–75°C and catalyst concentrations of 1–5% by mass fraction. These are processing parameters, not dosage levels.
Food emulsifier use (broader class): Industry provided EFSA with data on use levels (n = 1,024) of mono- and di-glycerides of fatty acids (E 471) in foods for 46 out of 84 food categories in which E 471 is authorized. These data cover glycerides broadly; DGMO-specific use levels in authorized foods are not reported separately in the reviewed literature.

9. Regulatory Status and Safety Considerations

Regulatory Classification

Diglycerol monooleate is classifiable as E475 (polyglycerol esters of fatty acids), a nonionic surfactant recognized within the European food additive regulatory system. The broader class of mono- and di-glycerides of fatty acids (E471), to which structurally related compounds belong, has received extensive regulatory evaluation:

In 2017, the European Food Safety Authority (EFSA) re-evaluated the safety of mono- and diglycerides and concluded that there is no need to establish a numerical ADI and there is no safety concern for the reported food uses. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) has set an ADI as "not limited" due to the safety of these ingredients.

EFSA concluded in 2017 that there was no need to set a numerical Acceptable Daily Intake (ADI) concentration and that there was no risk to health for the European population at current levels.

Glycerol monooleate and related glycerides are classified as GRAS (generally recognized as safe) due to their biodegradability, biocompatibility, and minimal toxicity. DGMO itself, while not independently listed as GRAS, falls within the general class of polyglycerol fatty acid esters that regulatory bodies have assessed favorably.

Toxicological Profile

No independent, published toxicological studies specifically evaluating DGMO in animals or humans were identified. The safety assessment necessarily draws on the profiles of the constituent components and structurally analogous compounds:

Oleic acid: A common dietary fatty acid, oleic acid is metabolized normally via β-oxidation and incorporation into glycerophospholipids and triglycerides. It presents no known toxicity at dietary levels.
Diglycerol: A condensation product of glycerol, diglycerol is structurally related to glycerol (a GRAS substance). No specific toxicity studies for diglycerol as an isolated compound were identified in the peer-reviewed sources searched.
Glyceryl oleate (closest monoglyceride analog): A single exposure of undiluted glyceryl oleate in animal dermal irritation studies produced only minimal irritation. Daily applications of a 25% corn oil solution of a formulation containing glyceryl oleate for 20 days produced severe dermal irritation in rabbits. In a 4-week dermal toxicity/phototoxicity study, product formulations containing up to 5% glyceryl oleate produced slight reversible dermal irritation.

Glycerol monooleate-based gels offer excellent biocompatibility but are prone to oxidation. By extension, DGMO-containing preparations containing the same oleic acid moiety would be expected to share susceptibility to lipid oxidation under inappropriate storage conditions (heat, light, oxygen exposure). This is a formulation stability concern, not a direct toxicity.

Environmental Profile

Glyceryl monooleate has been found not to be persistent, bioaccumulative, and toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards. While this assessment is for GMO, not DGMO specifically, the shared lipid structure and documented biodegradability of polyglycerol fatty acid esters suggest a similarly benign environmental profile for DGMO. The growing interest in environmentally friendly products has increased interest in biodegradable nonionic surfactant products such as polyglycerol fatty acid esters.

Potential Interactions and Considerations

No drug–DGMO or supplement–DGMO interactions have been documented in peer-reviewed clinical literature. As an emulsifying lipid, DGMO-based formulations have the theoretical capacity to alter the absorption of co-administered lipophilic molecules by modifying their physical presentation and solubilization in the gastrointestinal tract — a property that is the basis of its pharmaceutical interest but that has not been systematically studied for DGMO in clinical settings.

The challenges of scalability, long-term stability, and clinical translation remain unresolved for DGMO-based lipid crystalline nanoparticle formulations more broadly, meaning that while promising applications are under investigation, no DGMO-based product has yet completed clinical development at the time of the most recent available literature.

10. Summary of Evidence Strength

Physicochemical and materials science: Strong. Extensive peer-reviewed literature characterizes DGMO's phase behavior, liquid crystalline structure, emulsification properties, and nanoparticle formation.
Drug delivery (preclinical): Moderate–preliminary. Multiple in vitro and materials-characterization studies support the concept of DGMO-based sponge nanoparticles; no human clinical trial evidence exists.
Food additive safety (class): Strong (for the broader class). EFSA and JECFA have evaluated mono- and di-glycerides and polyglycerol esters extensively; DGMO-specific safety data are limited but the constituent components and structural analogs are well characterized.
Dietary supplement or nutraceutical efficacy: Absent. No human clinical trials using DGMO as a dietary supplement or nutraceutical ingredient were identified in any searched database.
Cosmetic/topical use: Weak–preliminary. Indirect support from studies on structurally related glycerol monooleate and general glyceride safety data; no DGMO-specific clinical dermatology trials found.

References

Health Conditions

Health conditions that Diglycerol monooleate may help support.

No conditions available.

Body Systems

Body systems that Diglycerol monooleate may help support.

No body systems available.